Major Depressive Disorder. Major depressive disorder, recurrent, mild
Conditions
Interventions
Intervention 1: Intervention group: in this group sertralin(sobhan pharmaceutical company)with a final up to 100 mg and atorvastatin 20mg once a day and during 8 weeks are prescribed. Intervention 2:
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: ? Age 20 to 55 years ? People with Major depressive disorder based on DSM-5 Criteria and clinical interview ? Lack of obvious and serious medical illness based on medical history, medications used, and history of hospitalization in a clinical interview ? Use of any agent or drugs that may have any interactions with sertralin or atorvastatin pharmacokineticlly or pharmacodinamiclly. ? Absence of active suicidal thoughts ? Absence of psychotic symptoms ? No symptoms of severe anxiety or panic disorder based on history and patients self report ? Having Hamilton rating scale for depression above 7 at the beginning of treatment
Exclusion criteria
Exclusion criteria: ? Existence of a serious uncontrolled medical condition based on medical history, medication use, and history of hospitalization in clinical interviews such as hypo and hyperthyroidism, epilepsy, diabetes, hypertension ? Co-occurrence of other obvious psychiatric disorders including bipolar or mixed mood disorders, severe anxiety disorders, and psychosis ? Existence of symptoms of severe anxiety or panic based on the statements of the patient and their companions in the clinical interview ? History of the mania Period ? Existence of psychotic symptoms associated with depression ? People with suicidal acts or thoughts or suicides at the start of the study ? Contraindications to atorvastatin ? Long-term use of psychiatric and non-psychiatric drugs that interfere with the drugs prescribed in this study ? Take other non-steroidal anti-inflammatory drugs now ? Active and current history of alcohol or drug use ? People with mental retardation or other cognitive and neurological disorders such as delirium, uncontrolled seizures, head trauma, seizure disorders (other than those associated with fever), and neurodegenerative diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression severity score in Hamilton Rating Scale for depression. Timepoint: Before intervention and 4, 8 weeks after intervention. Method of measurement: Hamilton Rating Scale And DSM5 Criteria. | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression severity score in Hamilton Rating Scale for depression. Timepoint: Before intervention and 4,8 weeks after intervention. Method of measurement: Hamilton Rating Scale for depression. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Noruzian
Mazandaran University of Medical Sciences
Outcome results
None listed